VIR-1111 is under clinical development by Vir Biotechnology and currently in Phase I for Human Immunodeficiency Virus (HIV) Infections (AIDS). According to GlobalData, Phase I drugs for Human Immunodeficiency Virus (HIV) Infections (AIDS) have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how VIR-1111’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

VIR-1111 overview

VIR-1111 is under development for the prevention of Human Immunodeficiency Virus (HIV) Infections (AIDS). It is administered via subcutaneous route. It is developed based on cytomegalovirus (CMV) vector-based technology. The drug candidate was also under development for the prevention of cytomegalovirus infections.

Vir Biotechnology overview

Vir Biotechnology (Vir) is a biotechnology company which carries out the development of therapeutic products to prevent and treat serious infectious diseases. It develops treatments for viral and bacterial diseases and induce protective and therapeutic immune responses. The company includes in multi-program, multi-platform approach. Vir focuses on chronic infectious diseases including hepatitis B, tuberculosis, HIV; respiratory diseases, including influenza, respiratory syncytial virus (RSV) and metapneumovirus (MPV), healthcare-acquired infections. It has operations in Portland, Oregon, Boston, Massachusetts, Bellinzona, Switzerland. Vir is headquartered in San Francisco, California, the US.

For a complete picture of VIR-1111’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.